Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals reported 2025 core revenue up 6% to $3.35 billion and core operating profit up 3% to $741 million, driven by double-digit growth in its Branded unit and solid performance in injectables and Hikma Rx across North America, MENA and Europe. Despite a drop in reported operating profit due to legal settlements and some margin pressure in Injectables, the group maintained a robust balance sheet, raised its dividend 5% and launched 84 products including its first US biosimilar.
The company announced a $250 million share buyback for 2026 and outlined modest group revenue and profit growth targets, while withdrawing previous medium-term guidance following a strategic review of its Injectables business. A sweeping leadership reshuffle will see Executive Chairman Said Darwazah focus solely on the CEO role, a new chair appointed, regional deputy CEOs created and an acting CFO installed, signalling a push for greater agility and accountability as Hikma seeks to strengthen long-term performance and capitalise on biosimilar and specialty injectables opportunities.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-headquartered multinational generic and branded medicines manufacturer with a strong presence in North America, the Middle East and North Africa, and Europe. The company focuses on injectables, branded drugs and the Hikma Rx generics segment, and positions itself as a leading licensing partner and investor in innovative health technologies through its venture capital arm.
Average Trading Volume: 737,137
Technical Sentiment Signal: Hold
Current Market Cap: £3.64B
Learn more about HIK stock on TipRanks’ Stock Analysis page.